Gilead Sciences Inc. reported that fourth-quarter sales of its hepatitis C virus (HCV) therapies halved since last year, falling to $1.5 billion from $3.2 billion in the fourth quarter of 2016 as new competition arrived on the scene and fewer patients started treatment.